IR Style Guide

News & Events

Corporate Presentation
Corporate Presentation - October 2019
News Releases

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

November 7, 2019

Net revenue for ELZONRIS ® was $13.3 million for the third quarter New patient starts estimated to have increased greater than 20% from last quarter Conference call and live webcast scheduled for tomorrow, Friday November 8 th , at 8:00 AM ET NEW YORK , Nov.

Additional Formats
PDF Version

Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

November 6, 2019

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp; SL-401), a novel targeted therapeutic

Additional Formats
PDF Version

Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

November 5, 2019

NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on Friday,

Additional Formats
PDF Version

Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

October 8, 2019

NEW YORK , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS ® (tagraxofusp) clinical data from the pivotal trial

Additional Formats
PDF Version

Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

October 1, 2019

NEW YORK , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data on the felezonexor (SL-801) Phase 1 trial in

Additional Formats
PDF Version

Upcoming Events
More events are coming soon.
Past Events